Cargando…

Overcoming the Intrinsic Gefitinib-resistance via Downregulation of AXL in Non-small Cell Lung Cancer

BACKGROUND: Resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib, is a limited factor in the treatment of non-small-cell lung cancer (NSCLC) patients. Therefore, ongoing studies are trying to identify EGFR-TKIs-resistant mechanisms and to discover...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jeong, Inae, Song, Jayoung, Bae, Song Yi, Lee, Sang Kook
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Society of Cancer Prevention 2019
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6951316/ https://www.ncbi.nlm.nih.gov/pubmed/31950021 http://dx.doi.org/10.15430/JCP.2019.24.4.217

Ejemplares similares

Targeting the degradation of AXL receptor tyrosine kinase to overcome resistance in gefitinib-resistant non-small cell lung cancer
por: Bae, Song Yi, et al.
Publicado: (2015)

Marsdenia tenacissima extract overcomes Axl- and Met-mediated erlotinib and gefitinib cross-resistance in non-small cell lung cancer cells
por: Han, Shu-Yan, et al.
Publicado: (2017)

Axl-altered microRNAs regulate tumorigenicity and gefitinib resistance in lung cancer
por: Wang, Y, et al.
Publicado: (2014)

244-MPT overcomes gefitinib resistance in non-small cell lung cancer cells
por: Zhang, Yi, et al.
Publicado: (2015)

AXL degradation in combination with EGFR-TKI can delay and overcome acquired resistance in human non-small cell lung cancer cells
por: Kim, Donghwa, et al.
Publicado: (2019)

Losmapimod Overcomes Gefitinib Resistance in Non-small Cell Lung Cancer by Preventing Tetraploidization
por: Yeung, Yiu To, et al.
Publicado: (2018)

Mechanism research of miR‐34a regulates Axl in non‐small‐cell lung cancer with gefitinib‐acquired resistance
por: Xiong, Ran, et al.
Publicado: (2019)

Targeting STAT3 signaling overcomes gefitinib resistance in non-small cell lung cancer
por: Liu, Zhe, et al.
Publicado: (2021)

Down-regulation of SerpinB2 is associated with gefitinib resistance in non-small cell lung cancer and enhances invadopodia-like structure protrusions
por: Bae, Song Yi, et al.
Publicado: (2016)

Atorvastatin overcomes gefitinib resistance in KRAS mutant human non-small cell lung carcinoma cells
por: Chen, J, et al.
Publicado: (2013)

Blockade of AXL activation overcomes acquired resistance to EGFR tyrosine kinase inhibition in non-small cell lung cancer
por: Wang, Feng, et al.
Publicado: (2019)

Efficacy of chemotherapy plus gefitinib treatment in advanced non-small-cell lung cancer patients following acquired resistance to gefitinib
por: SONG, ZHENGBO, et al.
Publicado: (2013)

Combined treatment with N‐acetylcysteine and gefitinib overcomes drug resistance to gefitinib in NSCLC cell line
por: Li, Jun, et al.
Publicado: (2019)

6-Shogaol Overcomes Gefitinib Resistance via ER Stress in Ovarian Cancer Cells
por: Kim, Tae Woo, et al.
Publicado: (2023)

TIP30 overcomes gefitinib resistance by regulating cytoplasmic and nuclear EGFR signaling in non–small‐cell lung cancer
por: Shuai, Shuai, et al.
Publicado: (2021)

Targeting AXL overcomes resistance to docetaxel therapy in advanced prostate cancer
por: Lin, Jian-Zhong, et al.
Publicado: (2017)

Losmapimod: A Novel Clinical Drug to Overcome Gefitinib-Resistance
por: Nishimura, Yukio
Publicado: (2018)

Angiogenic activities are increased via upregulation of HIF-1α expression in gefitinib-resistant non-small cell lung carcinoma cells
por: Cha, Jeong Eun, et al.
Publicado: (2021)

AUY922 Effectively Overcomes MET- and AXL-Mediated Resistance to EGFR-TKI in Lung Cancer Cells
por: Choi, Yun Jung, et al.
Publicado: (2015)

AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells
por: Taniguchi, Hirokazu, et al.
Publicado: (2019)

Targeting PAR2 Overcomes Gefitinib Resistance in Non-Small-Cell Lung Cancer Cells Through Inhibition of EGFR Transactivation
por: Jiang, Yuhong, et al.
Publicado: (2021)

Marine Actinomycetes-Derived Secondary Metabolites Overcome TRAIL-Resistance via the Intrinsic Pathway through Downregulation of Survivin and XIAP
por: Elmallah, Mohammed I. Y., et al.
Publicado: (2020)

Curcumin overcome primary gefitinib resistance in non-small-cell lung cancer cells through inducing autophagy-related cell death
por: Chen, Ping, et al.
Publicado: (2019)

Trifolium Flavonoids Overcome Gefitinib Resistance of Non-Small-Cell Lung Cancer Cell by Suppressing ERK and STAT3 Signaling Pathways
por: Wu, Zhiqiang, et al.
Publicado: (2020)

Synergistic induction of apoptosis by salinomycin and gefitinib through lysosomal and mitochondrial dependent pathway overcomes gefitinib resistance in colorectal cancer
por: Zou, Zheng-Zhi, et al.
Publicado: (2015)

Post-Progression Survival in Patients with Non-Small Cell Lung Cancer with Clinically Acquired Resistance to Gefitinib
por: Kim, Hyojeong, et al.
Publicado: (2013)

Chemotherapy confers a conserved secondary tolerance to EGFR inhibition via AXL-mediated signaling bypass
por: Aldonza, Mark Borris D., et al.
Publicado: (2021)

Co-delivery of Gefitinib and chloroquine by chitosan nanoparticles for overcoming the drug acquired resistance
por: Zhao, Liang, et al.
Publicado: (2015)

Inhibiting proliferation of gefitinib-resistant, non-small cell lung cancer
por: Sudo, Makoto, et al.
Publicado: (2013)

Yang-Yin-Jie-Du decoction overcomes gefitinib resistance in non-small cell lung cancer via down-regulation of the PI3K/Akt signalling pathway
por: Chen, Shu-yi, et al.
Publicado: (2021)

Targeting HER2-AXL heterodimerization to overcome resistance to HER2 blockade in breast cancer
por: Adam-Artigues, Anna, et al.
Publicado: (2022)

Resveratrol overcomes gefitinib resistance by increasing the intracellular gefitinib concentration and triggering apoptosis, autophagy and senescence in PC9/G NSCLC cells
por: Zhu, Yinsong, et al.
Publicado: (2015)

Gefitinib in Non Small Cell Lung Cancer
por: Costanzo, Raffaele, et al.
Publicado: (2011)

Reversal of Cisplatin Resistance by Epigallocatechin Gallate Is Mediated by Downregulation of Axl and Tyro 3 Expression in Human Lung Cancer Cells
por: Kim, Kyung-Chan, et al.
Publicado: (2014)

Overexpression of CTEN is associated with gefitinib resistance in non-small cell lung cancer
por: Lu, Xiangdong, et al.
Publicado: (2021)

Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer
por: Yokouchi, Hiroshi, et al.
Publicado: (2007)

Chloroquine Enhances Gefitinib Cytotoxicity in Gefitinib-Resistant Nonsmall Cell Lung Cancer Cells
por: Tang, Mei-Chuan, et al.
Publicado: (2015)

Role of AXL expression in non-small cell lung cancer
por: Qu, Xiaohan, et al.
Publicado: (2016)

Downregulation of MicroRNA-135 Promotes Sensitivity of Non-Small Cell Lung Cancer to Gefitinib by Targeting TRIM16
por: Wang, Ning, et al.
Publicado: (2018)

Synergistic Effect of HAD-B1 and Afatinib Against Gefitinib Resistance of Non-Small Cell Lung Cancer
por: Song, Si Yeon, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_b3jdhquihrcu2589k906p30nrr